Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2026 interim financial results and provided corporate updates.
A welcome email is on its way. If you don't see it, please check your junk folder.
During 2026H1, we remained steadfast in tackling patients’ “unmet medical needs” and realizing our goal of “improving quality, reducing cost and enhancing efficiency.” We continued to ensure all-rounded, high-quality compliance, and made breakthrough progress in discovery, clinical development and commercialization of innovative drugs and business operations with accelerating international development.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.
